Revolution Medicines reports positive results from daraxonrasib trials in metastatic pancreatic cancer, with strong response rates and consistent safety data.
Latest Ratings for RVMD
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Stifel | Upgrades | Hold | Buy |
| Nov 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Sep 2021 | Stifel | Initiates Coverage On | Hold |
